PP12613: A Potential Drug Target and Biomarker for the Treatment of Alzheimer's Disease

Target Name: PP12613

NCBI ID: G100192379

PP12613

Other Name(s): uncharacterized LOC100192379 | Uncharacterized LOC100192379

PP12613: A Potential Drug Target and Biomarker for the Treatment of Alzheimer's Disease

Alzheimer's disease is a progressive neurological disorder that affects millions of people worldwide, primarily in old age. It is characterized by a gradual accumulation of neurofibrillary tangles and senile plaques in the brain, leading to progressive memory loss, decline in cognitive function, and eventual death. Currently, there is no cure for Alzheimer's disease, and existing treatments are only able to slow down the disease's progression and provide temporary relief of symptoms. As a result, there is a significant need for new and effective treatments that can prevent or reverse the effects of Alzheimer's disease.

PP12613 is a protein that has been identified as a potential drug target and biomarker for the treatment of Alzheimer's disease. In this article, we will discuss the nature of PP12613, its potential as a drug target, and its potential as a biomarker for the diagnosis and progression of Alzheimer's disease.

Nature of PP12613

PP12613, also known asProtective Enigma 12613, is a protein that is expressed in the brain and has been shown to play a role in the development and progression of Alzheimer's disease. The protein is composed of 214 amino acids and has a calculated molecular mass of 33.9 kDa. It is expressed in the brain and has been shown to localize to the endoplasmic reticulum (ER) and the nuclear envelope (NE) in the brain.

PP12613 has been shown to interact with several other proteins, including the protein T-shirt, which is involved in the transport of various proteins to the endoplasmic reticulum. It has also been shown to interact with the protein S100, which is involved in the regulation of cellular signaling pathways.

Potential as a Drug Target

PP12613's interaction with the protein T-shirt has led to the hypothesis that it may be a drug target for the treatment of Alzheimer's disease. By inhibiting the activity of T-shirt, PP12613 could potentially prevent the delivery of neurofibrillary tangles and senile plaques to the brain, which is believed to contribute to the development and progression of Alzheimer's disease.

In addition, the interaction between PP12613 and the protein S100 suggests that it may also be a drug target for the treatment of Alzheimer's disease by regulating the activity of cellular signaling pathways. This could potentially involve the inhibition of neurofibrillary tangles and senile plaques, which are thought to play a role in the development and progression of Alzheimer's disease.

Potential as a Biomarker

PP12613 has also been shown to serve as a potential biomarker for the diagnosis and progression of Alzheimer's disease. The protein is expressed in the brain and has been shown to localize to the endoplasmic reticulum and the nuclear envelope in the brain. This suggests that it may be a suitable biomarker for the diagnosis of Alzheimer's disease, as the localization of the protein to these structures is thought to be a reliable indicator of its expression and presence in the brain.

In addition, the interaction between PP12613 and the protein S100 suggests that it may also be a useful biomarker for the assessment of the progression of Alzheimer's disease. By inhibiting the activity of S100, PP12613 could potentially slow down the progression of neurofibrillary tangles and senile plaques, which are thought to contribute to the development and progression of Alzheimer's disease.

Conclusion

In conclusion, PP12613 is a protein that has been identified as a potential drug target and biomarker for the treatment of Alzheimer's disease. Its interaction with the protein T-shirt and the protein S100 suggests that it may be a useful target for the inhibition of neurofibrillary tangles and senile plaques, which are thought to contribute to the development and progression of Alzheimer's disease. Further research is needed to confirm these findings and to determine the most effective method of treatment for this potential drug target.

Protein Name: Uncharacterized LOC100192379

The "PP12613 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about PP12613 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets